Erlotinib in Treating Patients With Progressive Glioblastoma Multiforme

Part of paid clinical trials in Chapel Hill, North Carolina.

Sponsor
UNC Lineberger Comprehensive Cancer Center
Study ID
NCT00227032
Phase
PHASE1
Status
Terminated

Conditions

  • Brain and Central Nervous System Tumors

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • erlotinib hydrochloride — DRUG
    300 mg, per day for subjects taking EIAEDs 150 mg, per day for those NOT taking EIAEDs

Study Details

RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I trial is studying the side effects and best dose of erlotinib in treating patients with progressive glioblastoma multiforme.

Key Dates

First listed
Sep 27, 2005
Start date
Sep 30, 2005
Status verified
Mar 2012
Primary completion
Feb 29, 2008
Completion
Mar 31, 2008

Study Design

Enrollment
10 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Subjects receiving EIAEDs
    Patients will be stratified according to concurrent use of enzyme inducing anti-epileptic drugs (EIAED)
  • Experimental: Subjects NOT taking EIAEDs
    Patients will be stratified according to concurrent use of enzyme inducing anti-epileptic drugs (EIAED)

Primary Outcome Measure

Progression-free survival [ Time Frame: 12 months ]

Locations (1)

FacilityCityStateZIPSite coordinators
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel HillChapel HillNorth Carolina27599-7295-

Find similar trials in Chapel Hill, NC

By research site
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill· Chapel Hill, NC

Related Studies